Metis Global Partners LLC Sells 6,217 Shares of Kenvue Inc. $KVUE

Metis Global Partners LLC lessened its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 6.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 88,721 shares of the company’s stock after selling 6,217 shares during the quarter. Metis Global Partners LLC’s holdings in Kenvue were worth $1,857,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Stratos Wealth Partners LTD. grew its stake in Kenvue by 10.4% in the 1st quarter. Stratos Wealth Partners LTD. now owns 14,857 shares of the company’s stock valued at $356,000 after buying an additional 1,396 shares in the last quarter. TruNorth Capital Management LLC bought a new position in shares of Kenvue in the first quarter worth $36,000. Pittenger & Anderson Inc. bought a new position in shares of Kenvue in the first quarter worth $30,000. CWM LLC grew its position in shares of Kenvue by 17.2% in the first quarter. CWM LLC now owns 29,342 shares of the company’s stock valued at $704,000 after purchasing an additional 4,309 shares in the last quarter. Finally, Bleakley Financial Group LLC raised its stake in shares of Kenvue by 6.2% during the 1st quarter. Bleakley Financial Group LLC now owns 72,580 shares of the company’s stock valued at $1,740,000 after purchasing an additional 4,228 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on KVUE shares. Deutsche Bank Aktiengesellschaft set a $18.00 target price on Kenvue in a research note on Friday, October 24th. Zacks Research raised shares of Kenvue to a “strong sell” rating in a report on Monday, August 11th. Citigroup cut their price objective on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, October 9th. Barclays upped their target price on shares of Kenvue from $17.00 to $18.00 and gave the stock an “equal weight” rating in a report on Monday. Finally, Edward Jones downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Kenvue presently has a consensus rating of “Hold” and a consensus target price of $20.23.

Kenvue Stock Down 0.5%

KVUE stock opened at $16.79 on Tuesday. The company’s 50 day moving average is $16.69 and its 200 day moving average is $20.22. The stock has a market cap of $32.17 billion, a price-to-earnings ratio of 22.39, a price-to-earnings-growth ratio of 2.46 and a beta of 0.71. The company has a current ratio of 0.98, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $25.17.

Kenvue (NYSE:KVUE) last announced its earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The business had revenue of $3.76 billion during the quarter, compared to analyst estimates of $3.83 billion. During the same period in the previous year, the business posted $0.28 earnings per share. Kenvue’s revenue for the quarter was down 3.5% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Sell-side analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th will be given a $0.2075 dividend. The ex-dividend date is Wednesday, November 12th. This represents a $0.83 annualized dividend and a yield of 4.9%. Kenvue’s payout ratio is 110.67%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.